A positive take on Indian Patent Law Amendments offered at R&D conference
Most of the press surrounding India’s looming deadline for full TRIPs compliance has been negative, focusing on the potential detrimental effects of extending patentability to pharmaceuticals.
In contrast, several positive comments were offered at the recent 18th national conference on in-house R&D in industry. The comments summarized in this article focus on the benefits that patent protection would bring to organizations focused on research and development, and to the Indian economy generally.
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
No comments yet.
Sorry, the comment form is closed at this time.